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OBJECTIVES: To identify Chlamydia trachomatis via polymerase chain reaction and a direct fluorescent antibody
assay in patients with vernal keratoconjunctivitis while comparing the efficacies of both tests for detecting
Chlamydia trachomatis in these conditions.
METHODS: Conjunctival scraping samples were obtained from 177 patients who were divided into two groups: a
vernal keratoconjunctivitis group (group A) and a control group (group B). The polymerase chain reaction and a
direct fluorescent antibody assay were performed. Sensitivity, specificity, receiver operating characteristic curves,
and areas under the curve were calculated for both tests in groups A and B. Receiver operating characteristic curves
were plotted using a categorical variable with only two possible outcomes (positive and negative).
RESULTS: Statistical analysis revealed a significant association between vernal keratoconjunctivitis and Chlamydia
trachomatis infection detected by a direct fluorescent antibody assay with high sensitivity and specificity. All
patients in group A with positive polymerase chain reactions also presented with positive direct fluorescent
antibody assays.
CONCLUSION: The association between vernal keratoconjunctivitis and Chlamydia trachomatis infection was
confirmed by positive direct fluorescent antibody assays in 49.4% of vernal keratoconjunctivitis patients and by
positive polymerase chain reactions in 20% of these patients. The direct fluorescent antibody assay detected
Chlamydia trachomatis in a higher number of patients than did the polymerase chain reaction. Although the
diagnosis of trachoma is essentially clinical, the disease may not be detected in vernal keratoconjunctivitis patients.
Due to the high frequency of chlamydial infection detected in patients with vernal keratoconjunctivitis, we suggest
considering routine laboratory tests to detect Chlamydia trachomatis in patients with severe and refractory allergic
disease.
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INTRODUCTION
Vernal keratoconjunctivitis (VKC) is a chronic ocular
allergy characterized by itching and conjunctival hyperemia
with papillary hypertrophy of the upper palpebral or tarsal
conjunctiva and/or limbus. It is frequently associated with
corneal involvement.1-3
Trachoma is a chronic follicular keratoconjunctivitis
characterized by the presence of follicles in the upper
palpebral conjunctiva and limbus. Mucous discharge may
be present, along with itching, which is less intense than
that experienced in VKC. Follicular necrosis and subcon-
junctival inflammation may lead to conjunctival scars, Arlt’s
lines and Herbert’s pits, which are pathognomonic features
of trachoma. Palpebral and secondary corneal involvement
may also be present.
Transmission occurs by direct eye-to-eye and hand-to-eye
contact, usually by contaminated ocular discharge, clothes,
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bed sheets, towels and the proliferation of flies in homes
and schools.4,5
The diagnosis of both VKC and trachoma is essentially
clinical. With trachoma, especially in endemic areas and in
chronic and cicatricial trachoma, clinical diagnosis is
straightforward. However, in the early stages of the
infection, due to its relatively benign and asymptomatic
course, it may not be easily differentiated from viral,
bacterial, or allergic conjunctivitis. In these cases, laboratory
tests become essential, especially direct fluorescent antibody
assays (DFAs).6,7
DFAs are easily performed but require adequate trans-
portation and storage of the samples in a refrigerator, a
fluorescent microscope, and well-trained personnel.
Polymerase chain reaction (PCR) has been suggested to
test for Chlamydia trachomatis that has both the specificity of
cell culture and a level of sensitivity similar to that of DFA.
PCR is an in vitro method for detecting DNA sequences by
enzymatic amplification of a specific fragment that can
synthesize more than one million copies of one DNA
sequence in a short period of time.
VKC and trachoma share many features. They both affect
school-age children and young adults in hot, dry climate
areas. They are characterized by chronic keratoconjunctivi-
tis, usually bilateral, that waxes and wanes throughout the
year.8,9 One key difference is that whereas VKC stimulates a
papillary reaction of the conjunctiva, trachoma stimulates a
follicular response. However, following the early follicular
hypertrophy of trachoma (phase TF), a papillary reaction
(phase TI) may cover the follicles. Also, follicles and papillae
may coexist. In these cases, giant papillae would be
dominant and would obscure the follicles. Limbal follicles
may also be obscured by the characteristic papillae and
edema of limbal VKC. In this phase, we believe that many
cases of trachoma may not be getting clinically diagnosed,
especially in the presence of a common comorbid papillary
disease such as VKC.
Ve´rin et al. first described a possible association between
VKC and trachoma in 1980.8 Later, in 1988, Friedlaender &
Cameron presented four cases of possible association.3 One
year later, Ve´rin et al. (1989) described 8 (23.5%) cases of
Chlamydia trachomatis infection confirmed the Wang and
Grayston technique in 34 patients with VKC.9
The possible association between VKC and trachoma was
not addressed again until 2000, when Melo et al. studied 72
patients with allergic conjunctivitis, 38 (52.8%) of whom had
a positive DFA for Chlamydia trachomatis.10 In that study,
the control group (60 patients) did not have any positive
DFAs. Statistical analysis identified a significant association
between the diseases.
The purpose of this study was to use PCR and DFA to
detect the presence of Chlamydia trachomatis in patients with
VKC compared with a control group and also to compare
the efficacies of both tests for detecting Chlamydia trachomatis
in patients with VKC.
MATERIALS AND METHODS
One hundred seventy-seven patients were divided into
two groups.
Group A consisted of 87 patients with VKC from the
Ocular Allergy Service of the Department of Ophthalmology.
Patients using topical or systemic antibiotics were excluded.
Patients were diagnosed with VKC using the following
criteria: a clinical history of chronic bilateral conjunctivitis (at
least one year) with seasonal exacerbations (i.e., itching,
photophobia, and foreign body sensation); hypertrophic
papillae at the superior palpebral conjunctiva and/or limbus;
and, eventually, Horner-Trantas dots, superficial punctate
keratitis and shield ulcers or corneal scars from shield ulcers.
Group B (the control group) consisted of 90 patients who
presented for regular eye examinations (refractometry) and
were neither complaining of allergic conjunctivitis nor
taking topical or systemic antibiotics.
All patients in groups A and B were informed of the
purpose of the study, and all patients signed an informed
consent. The institutional review ethical committee
approved this study.
Patients were asked about their disease length, symp-
toms, and familial and personal histories of atopy and other
ocular diseases.
The symptoms assessed included itching, tearing, photo-
phobia, discharge, and reduced visual acuity.
The following components were included in the examina-
tion: a measurement of visual acuity; slit lamp biomicro-
scopy to evaluate conjunctival hyperemia; a test for the
presence of papillae at the conjunctiva and/or limbus and
other conjunctival, limbal, and corneal alterations (follicles
and scars); tonometry; and a fundus examination. All
patients were examined by the same doctor.
All patients underwent tissue sampling for the detection
of Chlamydia trachomatis by DFA. The superior palpebral
conjunctiva of the right eye was scraped five times with a
Kimura spatula. The sample was then placed in a
demarcated circle on the appropriate slide, dried for 5
minutes, fixed with absolute methanol and stained with the
fluorescent monoclonal antibody (Microtrak-SyvaTM). After
30 minutes of incubation in a moist chamber at room
temperature, the slides were washed with distilled water
and were left to dry again. The samples were examined by
an experienced technician under immersion fluorescent
microscopy with epi-illumination at 1000X magnification.
The material was considered adequate when it included at
least 100 epithelial cells per field. The criterion for a positive
diagnosis was the presence of five or more elementary
bodies per sample.
The PCR was calibrated by obtaining a positive control
from a patient who had no allergic conjunctivitis and a
clinical diagnosis of trachoma, which was confirmed by a
positive DFA for Chlamydia trachomatis. The negative control
was obtained from a patient who presented with no signs or
symptoms of either trachoma or allergic conjunctivitis and
had a negative DFA for Chlamydia trachomatis. The positive
and negative controls were obtained to accurately calibrate
the PCR for the detection of Chlamydia trachomatis.
All patients in groups A and B had the superior palpebral
conjunctiva of their right eye scraped with a Dacron swab.
The part of the swab containing the collected material was
placed in a plastic tube with the transportation medium.
Samples were taken immediately to a Molecular Biology
laboratory within 4 hours after collection. The material was
processed according to the technique introduced by Bobo.11
For each sample, an initial PCR was performed to verify
the presence of b-human globin to avoid false negative
results. The primers had the following sequences: Primer
HGH1: 59 – TGCCTTCCCAACCATTCCCTTA – 39 and
Primer HGH2: 59 – CCACTCACGGATTTCTGTTGTGT-
TTC – 39. Detection of the fragment occurred at 420-bp long.
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In the samples in which b-human globin was detected, a
second PCR was performed to detect and amplify a highly
conserved region of the specific major outer membrane
protein (MOMP) for Chlamydia trachomatis. The sequences of
the primers used to detect Chlamydia trachomatis follow:
Primer 1: 59 - GAT AGC GAG CAC AAA GAG AGC TAA
– 39; Primer 2: 59 – TTC ACA TCT GTT TGC AAA ACA
CGG TCG AAA ACA AAG – 39; Primer 3: 59 - TCT GCT
TCC TCC TTG CAA GCA AGT CTG CC – 39; and Primer
4: 59 - CCA TAG TAA CCC ATA CGC ATG CTG – 39.
The amplified fragment was then examined by electro-
phoresis in agarose gel that was stained with ethidium
bromide. Detection of the fragment occurred at 151-bp
long.
Calculations of sensitivity and specificity were conducted,
and a receiver operating characteristic (ROC) curve was
plotted to evaluate and compare the diagnostic capabilities
of both laboratory tests. Sensitivity, specificity, ROC curves,
and areas under the curve were calculated with the
assumption that DFA is the gold standard for Chlamydia
spp. diagnosis. ROC curves were plotted using a categorical
variable with only two possible outcomes (positive and
negative), which can lead to underestimation of the area
under the curve. MedCalc software version 9.3.7.0 was used
for all calculations.
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of human
volunteers were followed during this research.
RESULTS
Clinical evaluation
Group A consisted of 87 patients with VKC. Patient ages
in this group ranged from 2 to 23 years (mean age= 9.6¡4.8
years); 74 patients (73.6%) were white, and 23 (26.4%) were
black; 27 (31.0%) were female, and 60 (69.0%) were male
(Table 1).
Group B (control group) consisted of 90 patients. Patient
ages ranged from 2 to 23 years (medium age = 9.0¡5.0
years); 45 patients (50.0%) were male, and 45 (50.0%) female;
68 patients (75.6%) were white, and 22 (24.4%) were black
(Table 1).
No statistical differences were identified between groups
A and B based on either race (x2 = 0, p= 1.0) or age (t= -0.862;
p=0.39). The majority of VKC patients (86.2%) were less
than 15 years old. In group B, 88.9% of the patients were
under the age of 15. Caucasians were predominant in both
groups (73.6% in group A and 75.6% in group B).
In group A, 69.0% of the patients were male, and in group
B, 50.0% of the patients were male. This difference between
the groups was statistically significant (x2= 5.831, p= 0.016).
All patients in group A presented with itching and red
eyes. Symptoms of corneal involvement (i.e., punctate
keratitis, superficial corneal opacities, shield ulcer, and
peripheral neovascularization) were identified in 15 patients
(17.2%). Seventeen patients (19.5%) in group A (i.e., patients
with VKC) had conjunctival and limbal scars (i.e., scars in
the upper tarsal conjunctiva and pits in the superior
limbus), both of which were suggestive of trachoma (TS).
Follicles (more than six), suggesting follicular trachoma
(TF), were identified in the upper tarsal conjunctiva in two
patients (2.3%) from group A. No patients presented with
typically trachomatous corneal opacities or palpebral
alterations.
Direct fluorescent antibody test
All samples had more than 100 epithelial cells per field
and were considered adequate for laboratory analysis.
In group A, 44 samples (50.6%) were negative (less than
five fluorescent elementary bodies), and 43 samples (49.4%)
were positive (more than five fluorescent elementary
bodies). Positive DFA was identified in all patients with
suggestive signs of trachoma (two patients with more than
six follicles in the upper tarsal conjunctiva and 13 of 17
patients with conjunctival and limbal scars). In group B, all
samples were negative.
Polymerase Chain Reaction
In group A, human b-globin was detected in 70 samples
(80.4%); 14 (20.0%) were positive for Chlamydia trachomatis.
In group B, human b globin was identified in 60 samples
(66.7%), one (1.7%) of which was PCR-positive for Chlamydia
trachomatis.
Correlating the clinical findings with the results of the
PCR, we observed that two patients from group A with
suggestive signs of TF had positive PCR results. The PCR
results were also positive in eight of the 17 patients with
suggestive TS.
Direct Fluorescent Antibody Assay vs. Polymerase
Chain Reaction
All patients in group A with positive PCR results also had
positive DFAs. Only one patient from group B with a
negative DFA had a positive PCR result (Figures 1 and 2)
Figure 3 displays ROC curves for DFA and PCR.
Areas under the ROC curves were 1.0 (95% CI= 0.958 to
1.000) for the DFA and 0.663 (95% CI = 0.553 to 0.761) for the
PCR. A pairwise comparison of ROC curves revealed a
difference of 0.337 (95% CI= 0.223 to 0.451, p,0.001).
The sensitivity and specificity of the DFA were 100 (95%
CI= 91.7 to 100) and 100 (95% CI= 91.9 to 100), respectively.
Table 1 - Distribution by sex and race of patients with vernal keratoconjunctivitis (Group A) and controls (Group B).
Group Sex Race
Female Male White Black
N % N % N % N %
A 27 31 60 69 64 73.6 23 26.4
B 45 50 45 50 68 75.6 22 24.4
Legend:
N: Number.
x2 = 5.831 (for sex); 0 (for race).
p=0.016 (for sex); 1 (for race).
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The sensitivity of the PCR was 23.56 (95% CI= 19.1 to 48.5),
and the specificity of the PCR was 100 (95% CI= 91.9 to 100).
DISCUSSION
In our study, as in previous publications, VKC occurred
more frequently in children less than 15 years old (86.25%)
and in males (69.0%).1,2 A clinical diagnosis of VKC was
made in all patients from group A, and they all reported
itching.
A clinical diagnosis of Chlamydia trachomatis infection
could also have been made by the presence of scars.
However, in the earlier stages of infection, the relatively
benign and asymptomatic course and the preponderance of
signs and symptoms of VKC could obfuscate the correct
diagnosis. In our study, scars suggestive of trachoma were
detected in 17 patients (19.5%) from group A.
All the samples that were prepared for DFA were used
because all had the minimum of 100 epithelial cells per field.
The presence of five or more fluorescent elementary bodies
was considered a positive result in the analysis of the
samples.6
In group A, 49.4% of the samples presented positive DFA,
and in group B, all 90 samples were negative. Of the 43
patients with positive DFA, 19 had suggestive clinical signs
of trachoma, and the majority of the remaining cases could
be diagnosed only by laboratory tests.
PCR is considered the most sensitive non-culture test for
the detection of Chlamydia trachomatis in non-ocular sam-
ples. Problems related to contamination and the presence of
DNA polymerase inhibitors, such as blood and lysozyme,
could result in false-negative and false-positive results. The
routine use of a negative control and an internal control (for
the detection of human b-globin) would eliminate the risk of
misreading for the methodology applied in this study.
Human b-globin was detected in 70 of the 87 samples
from group A and in 60 of the 90 samples from group B.
Therefore, 80.4% and 66.7% of the samples, respectively,
were used. Although many studies have used the plasmid
for DNA amplification, some Chlamydia trachomatis strains
with no plasmid have been described.7 Therefore, we opted
to amplify a conserved region of nucleotides in the MOMP
gene.
We obtained fewer positive PCRs than DFAs: 14 samples
in group A (corresponding to 20.0%) and 1 sample in group
B (corresponding to 1.7%).
Frequent questions raised by practitioners include
whether VCK causes trachoma, whether trachoma causes
VKC or whether their co-occurrence is merely coincidental.
These questions arise because both diseases affect the same
group of patients (i.e., school children in hot and dry areas).
Ve´rin et al. reported that Chlamydia trachomatis could act
as an allergen or as the trigger of an allergic process,
suggesting that a chronic chlamydial infection, which alters
the immunologic events on the ocular surface, could be
associated with the local allergic response.8,9
Friedlaender and Cameron observed that the infectious
nature of trachoma was not relevant in the pathogenesis of
VKC. Atopic patients, such as those with VKC, present with
some local or systemic immunological compromise, which
could explain the greater incidence of staphylococcal and
herpetic infections and possibly chlamydial infections.3 In
addition, the integrity of the epithelium is considered the
first line of defense of the ocular surface in many infectious
conditions. VKC patients have conjunctival alterations due
to chronic inflammation, vascular hyperpermeability, and
excoriation, all of which compromise the integrity of the
ocular surface, rendering the patient more susceptible to
secondary infections, such as trachoma.3
Another factor to be considered is that all VKC patients
present with itching as their main symptom, and they
excessively manipulate their eyes, thus transferring sig-
nificant numbers of microorganisms, possibly including
Chlamydia trachomatis, from their hands to their eyes.
Chlamydia trachomatis can also be carried by contaminated
secretions, which are commonly found in the eyes of VKC
patients.
SCARPI et al. observed in their study that itching was the
main symptom in trachoma patients (11.47%); they likely
also included some patients with concomitant trachoma and
allergic conjunctivitis.12
Rao et al. investigated the presence of Chlamydia
trachomatis in 127 patients with acute, chronic, and recurrent
conjunctivitis.5 Of the 22 patients with clinically diagnosed
allergic conjunctivitis, seven (31.8%) had a positive culture
for Chlamydia trachomatis.
Notably, DFA is still considered the gold standard for
Chlamydia trachomatis detection. Without it, clinical diag-
noses would have been made in only 19 of 43 patients
(44.2%) with positive DFAs, indicating that trachoma would
not have been diagnosed in 55.8% of patients. These cases
would have been treated as severe and refractory allergic
conjunctivitis.
Despite its low sensitivity in this study, DNA amplifica-
tion by PCR is still used for the detection of ocular
chlamydial infection; more recently, however, nucleic acid
amplification tests (NAATs) based on the amplification of
rRNA have been developed, providing a potential advan-
tage because bacterial rRNA is present at up to 10,000 times
the copy numbers of genomic DNA and at up to 1,000 times
the copy numbers of plasmid DNA. This development
opens a field of new opportunities for the detection of
chlamydial infections using these techniques.13,14
Figure 1 - Venn diagram from group A (43 DFA-positive results).
Figure 2 - Venn diagram from group B (1 positive PCR result).
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Although both trachoma and VKC have characteristic
periods of waxing and waning even without treatment, the
chronicity, the recurrent nature and the long duration of the
diseases can be highly disabling. Patients are disabled not
only by the severe symptoms in the acute phases but also by
the more frequent occurrences of complications, such as lid
abnormalities and conjunctival and corneal scars, which can
cause reduced visual acuity, impairing the acquisition of
reading skills in children.1,3
Trachoma is a self-limiting disease, resolving in approxi-
mately one year even without treatment. However, treat-
ment is essential to avoid recurrences, scars, and other
sequelae. Immunological diseases such as VKC are treated
with anti-allergic and anti-inflammatory drugs such as
corticosteroids that depress cell immunity and are impli-
cated in the control of infections and trachoma. In contrast,
trachoma is treated with antibiotics. Therefore, because the
treatments differ for VKC and trachoma, it is essential to
accurately determine their co-occurrence to initiate the
appropriate treatment.
Based on the population studied and the applied
methodologies, we report several findings. First, there was
an association between VKC and Chlamydia trachomatis
infection that was confirmed by positive DFAs in 49.4% of
VKC patients and by positive PCRs in 20.0% of patients.
Second, DFA detected Chlamydia trachomatis in a greater
number of patients than did PCR, making it the more
sensitive and specific test. Third, although the diagnosis of
trachoma is essentially clinical, the disease may not be
detected in some VKC patients. In conclusion, we suggest
considering laboratory tests to routinely detect Chlamydia
trachomatis by DFA in patients with severe and refractory
VKC.
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